Berger Montague Investigates Securities Class Action Lawsuit Against Rocket Pharmaceuticals

Berger Montague PC, a nationally recognized securities litigation firm, is investigating a newly filed securities class action lawsuit against Rocket Pharmaceuticals, Inc. The suit alleges that the company misled investors regarding critical safety disclosures tied to its RP-A501 gene therapy program. Rocket Pharmaceuticals, a biotechnology company focused on developing gene therapies for rare diseases, is accused of failing to inform investors of a substantial protocol change before a serious adverse event (SAE) and subsequent FDA clinical hold.

Key Takeaways:

  • The lawsuit was filed in the U.S. District Court for the District of New Jersey and alleges that Rocket Pharmaceuticals misled investors about safety disclosures related to its RP-A501 gene therapy program.
  • The company is accused of failing to disclose a protocol change that led to a serious adverse event (SAE) and an FDA clinical hold.
  • Rocket Pharmaceuticals' shares fell nearly 37% following the company's disclosure of a patient death in the trial.
  • Investors who purchased Rocket Pharmaceuticals securities between September 17, 2024 and May 26, 2025 may be eligible to seek recovery.
  • The deadline to apply for lead plaintiff is August 11, 2025.
  • Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
  • Berger Montague has offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, and Chicago.

Statistics:

  • Rocket Pharmaceuticals' shares fell 37% from $6.27 on May 23, 2025 to $2.33 on May 27, 2025.
  • The lawsuit was filed in the U.S. District Court for the District of New Jersey.
  • The deadline to apply for lead plaintiff is August 11, 2025.
  • Berger Montague has over 50 years of experience in securities class action litigation.

Sources:

  • Newsfile Corp. - July 25, 2025
  • Berger Montague, a nationally recognized securities litigation firm based in Philadelphia.